Carbetocin
Carbetocin, a drug developed by Levo Therapeutics, achieves statistically significant results in the treatment of hyperphagia following a phase 3 trial.
Carbetocin, a drug developed by Levo Therapeutics, achieves statistically significant results in the treatment of hyperphagia following a phase 3 trial.
Top line phase 3 results for DCCR, a drug to treat hyperphagia, shows statistically significant improvements in hyperphagia for patients with severe symptoms. It also… Read More »Phase 3 DCCR trial top line results